Discussion

The possibility that NF-I is linked to markers on chromosome 4q appears to have been excluded by the data in table 2, a conclusion consistent with the findings of other investigators. In addition, the genes for TGFA, EGF, GRL, and EGFR, which may be considered 'candidate genes' for NF-I, show no evidence of close linkage. Eleven other loci selected on the basis of convenience also show no evidence of linkage.

References

Correspondence and requests for reprints to Dr V M Riccardi, NF Program, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, USA.

Linkage analysis of British and Indian families with Von Recklinghausen neurofibromatosis


From *the Institute of Cancer Research, Haddow Laboratories, Clifton Avenue, Sutton, Surrey SM2 5PX; †the MRC Research Unit for Inherited Skeletal Disorders, Department of Human Genetics, University of Cape Town Medical School, Observatory 7925, South Africa; and ‡the Department of Genetics, University of Leicester, Leicester LE1 7RH.

SUMMARY Linkage analysis has been undertaken in two British and three South African Indian families with Von Recklinghausen neurofibromatosis. Eleven polymorphic DNA probes were studied, including both random DNA sequences and candidate oncogenes. Although no evidence for linkage of these probes to the disease was detected, substantial exclusion regions were established on six of the chromosomes studied.
Linkage analysis of British and Indian families with Von Recklinghausen neurofibromatosis (VRNF) is a relatively common autosomal dominant disorder characterised by café au lait spots, cutaneous neurofibromas, and an increased risk of central nervous system tumours. The pathogenesis of the disorder is unknown and no laboratory diagnostic test is available. Several genetic linkage studies have been undertaken in order to map the locus of the VRNF gene, but none of these has detected a significant linkage between a marker and the disorder. We have therefore tested a further 11 polymorphic DNA markers as part of the international effort to locate the affected gene.

Materials and methods

Families were ascertained through the British Neurofibromatosis Patients’ Association, LINK, and the records of the Department of Human Genetics, University of Cape Town Medical School. The criteria for the diagnosis of VRNF were as follows. (1) In adults, six or more café au lait spots >1.5 cm in diameter and multiple cutaneous neurofibromas. (2) In children, an affected parent and six or more café au lait spots >1.5 cm in diameter.

All subjects included in the linkage analysis were more than five years old. Blood specimens were obtained from two British families and three South African families of Indian descent. A total of 73 subjects was sampled, which included 37 affected subjects and 62 potentially informative meioses. DNA isolation, blotting, and hybridisation were performed as described previously. The probes used were as follows: seven locus specific minisatellite sequences (unpublished data), the hypervariable region 3' to the α-globin genes, the erb A2 and sis oncogenes, and 22c1-18, which is a random sequence on chromosome 22.

Likelihood computations were carried out using a modification of the LINKAGE programme. The VRNF gene was assumed to have a population frequency of $2 \times 10^{-4}$ and a penetrance of 100%. Rapid computation of lod scores for the minisatellite sequences, which have multiple alleles, was facilitated by recording the genotypes of some subjects so that at most four alleles were used.

Results and discussion

The lod scores at recombination fractions from 0 to 0.4 are shown in the table. No evidence for linkage of any of the probes tested to the VRNF gene was obtained. However, use of the highly polymorphic minisatellite probes has established large regions of exclusion on chromosomes 1, 5, 6, 7, 11, and 12. Assuming that the exclusions do not overlap and that none of the probes is located near the end of a chromosome, a total of 236 cM (approximately 8% of the human genome) has been excluded for VRNF at a lod score of -2 or less. The data also appear to exclude the sis and erb A2 oncogenes as candidate genes for VRNF. Future work will concentrate on the use of probes with high frequency restriction fragment length polymorphisms from regions of the genome where large exclusions for the VRNF gene have not been reported. The exclusion map published in this issue will facilitate the search.

We would like to thank Margaret Ponder for assistance in obtaining the family material, D Higgs for the hybridisations with the α-globin gene HVR probe, and M Ormerod for advice on a linkage computer programme. We also thank P Middleton, A Hall, and C Buys for the erb A2, sis, and 22c1-18 probes. This work was supported by grants from the Cancer Research Campaign, the Medical Research Council, and ‘LINK’, the neurofibromatosis associa-

**Table:** Lod scores for linkage between VRNF and 11 polymorphic DNA probes.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Probe</th>
<th>Chrom*</th>
<th>Z at recombination fraction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>D1S7</td>
<td>λMS1</td>
<td>1p</td>
<td>×</td>
</tr>
<tr>
<td>D1S8</td>
<td>λMS2</td>
<td>1q</td>
<td>×</td>
</tr>
<tr>
<td>D5S3</td>
<td>λMS3</td>
<td>5</td>
<td>×</td>
</tr>
<tr>
<td>D6*</td>
<td>λMS9</td>
<td>6</td>
<td>×</td>
</tr>
<tr>
<td>D7S21</td>
<td>λMS1</td>
<td>7pter-q22</td>
<td>×</td>
</tr>
<tr>
<td>D11*</td>
<td>pMS1</td>
<td>11pter-qter</td>
<td>×</td>
</tr>
<tr>
<td>D1S11</td>
<td>λMS42</td>
<td>12</td>
<td>×</td>
</tr>
<tr>
<td>HBA</td>
<td>pgHVR 64</td>
<td>16p13</td>
<td>×</td>
</tr>
<tr>
<td>ERBA2</td>
<td>pHEA2</td>
<td>17q11</td>
<td>×</td>
</tr>
<tr>
<td>SIS</td>
<td>V-SIS</td>
<td>22q12-13</td>
<td>×</td>
</tr>
<tr>
<td>D22S10</td>
<td>22c1-18</td>
<td>22</td>
<td>×</td>
</tr>
</tbody>
</table>

*These minisatellite probes have not yet been assigned HGM symbols. The regional assignments of λMS1 and λMS2 are provisional.

*Chrom = chromosomal localisation.
tion. AJJ is a Lister Institute Research Fellow. The minisatellite probes are the subject of Patent Applications and commercial enquiries should be addressed to the Lister Institute of Preventive Medicine, Brockley Hill, Stanmore, Middlesex HA7 4JD, UK.

References

Correspondence and requests for reprints to Dr C G P Mathew, Institute of Cancer Research, Haddow Laboratories, Clifton Avenue, Sutton, Surrey SM2 5PX.

Linkage analysis of neurofibromatosis

S KITTUR*, M L LUBS†, M BAUER†, A CHAKRAVARTI‡, AND H KAZAZIAN*

From *the Department of Pediatrics, Johns Hopkins Institution, Baltimore, Maryland; †the Department of Genetics, University of Miami, Florida; and ‡the Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Summary

Linkage analysis of neurofibromatosis was performed using genes on chromosomes 1, 8, 11, and 12. No linkage was found between NF and C-myc, AT 3, IGF-1, PTH, and gamma globin genes. Evidence for linkage was found between C-ets 1, on the long arm of chromosome 11 and NF in two families with a lod score of 1.88 at θ=0. More families are being studied to confirm this linkage.

Neurofibromatosis (NF) is one of the common autosomal dominant neurological disorders with a frequency of approximately 1 in 3000. The disease is mainly characterised by café au lait spots and neurofibromas. These patients have an unusually high frequency of malignancy compared to the normal population. The intriguing question is, what gene do they carry that predisposes them to malignancy? In order to localise the gene for NF, linkage analysis using DNA markers was performed.

Three multi-generation families shown in table 1 were used.

Oncogene C-myc, insulin like growth factor-1, antithrombin-3, parathyroid hormone, and gamma globin genes1–5 were not linked to neurofibromatosis in our families. The lod scores are shown in table 2.

We found a positive lod score of 1.88 with oncogene C-ets 1b in two informative families (no recombinants observed in six informative meioses). These data provide suggestive evidence that the NF

Received for publication 23 March 1987.
Accepted for publication 24 March 1987.